R&D Partnering Areas of Interest

**Gastroenterology**
- Gut Inflammation (IBD; Celiac Disease; microbiome)
- Motility Disorders
- Liver Disease (F3/F4 NASH; Wilson’s)
- Cell/gene therapy

**Area of Interest**
- IBS
- Visceral pain
- Metabolic NASH
- PD and MS constipation
- Chronic idiopathic constipation
- Phage therapeutics

**Not Seeking**

**Oncology**
- Hematologic Malignancies
- Innate immune targets, therapies, and platforms
- Allogeneic cell therapies
- Novel immune engagers
- Translational tools

**Area of Interest**
- Reformulations
- Chemotherapies
- Malignancies of the CNS

**Neuroscience**
- Precision medicine approaches to Neurodegeneration (AD/PD)
- Huntington’s Disease
- Hereditary ataxias (FA)
- Neuromuscular (ALS, DM1, FSHD, DMD)

**Area of Interest**
- Pain, Stroke, TBI
- MS
- Psychiatry

**Not Seeking**

**Rare Disease**
- Rare Immunology
- Rare Hematology
- LSDs/IEM
- Innovative advances in gene therapy/gene-editing/cell therapy

**Area of Interest**
- Reformulations
- Repurposed assets/targets
- Therapies with only modest improvements to standard of care
- Symptomatic treatments not addressing fundamental disease biology

**Drug Delivery Technologies**
- Particles – LNPs, Liposomes, Exosomes
- Energy Systems – Ultrasound, Magnetic, Thermal
- Materials – Hydrogels, Scaffolds, Devices
- Blood Brain Barrier

**Research Areas of Interest**
- Oral biotherapeutics – gut and liver delivery
- Tumor Targeting – Oncology
- Rare Disease – efficient gene and cell delivery

**Immunology**
- Immune tolerance therapies and platform technologies
- Targeted modulators to downregulate immune response – cytokines, checkpoint intervention, depletion

**Research Areas of Interest**
- Allogeneic compatibility enhancement
- Pathogenic antibody mitigation
- Gene-editing technologies with reduced immunogenicity
- Autoimmunity, Rare Disease

**Not Seeking**

**Area of Interest**
- Reformulations
- Chemotherapies
- Malignancies of the CNS

**Rare Immunology**
- Rare Hematology
- LSDs/IEM
- Innovative advances in gene therapy/gene-editing/cell therapy

**Area of Interest**
- Reformulations
- Repurposed assets/targets
- Therapies with only modest improvements to standard of care
- Symptomatic treatments not addressing fundamental disease biology

**Rare Hematology**
- LSDs/IEM
- Innovative advances in gene therapy/gene-editing/cell therapy

**Area of Interest**
- Reformulations
- Repurposed assets/targets
- Therapies with only modest improvements to standard of care
- Symptomatic treatments not addressing fundamental disease biology

**Rare Immunology**
- Rare Hematology
- LSDs/IEM
- Innovative advances in gene therapy/gene-editing/cell therapy

**Area of Interest**
- Reformulations
- Repurposed assets/targets
- Therapies with only modest improvements to standard of care
- Symptomatic treatments not addressing fundamental disease biology

**Rare Hematology**
- LSDs/IEM
- Innovative advances in gene therapy/gene-editing/cell therapy